Rhizen Pharmaceuticals AG Announces Promising Interim Data Presentation From an Ongoing Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients At ESMO Breast Cancer Meeting 2022
Rhizen Pharma reports encouraging initial results from an ongoing phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K d/? inhibitor with additional SIK3 inhibitory activity)